1. Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer
   Ramya Ayyalasomayajula et al, 2024, Cancers CrossRef
2. Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions
   Michelle L. McKeague et al, 2024, Antibodies CrossRef
3. The Formation of Stable Lung Tumor Spheroids during Random Positioning Involves Increased Estrogen Sensitivity
   Balkis Barkia et al, 2024, Biomolecules CrossRef
4. MUC1 promotes cancer stemness and predicts poor prognosis in osteosarcoma
   Jian Liu et al, 2023, Pathology - Research and Practice CrossRef
5. Progress in the Study of Abnormal Expression of Mucin in Gastric Mucosal Lesions
   晓慧 秦, 2024, Advances in Clinical Medicine CrossRef
6. Drug repositioning in castration-resistant prostate cancer using systems biology and computational drug design techniques
   Javad Rafiee et al, 2025, Computational Biology and Chemistry CrossRef
7. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine
   Saru Basnet et al, 2024, Molecular Therapy CrossRef
8. Biomarkers in high grade serous ovarian cancer
   Mark Bates et al, 2024, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
9. Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer
   Anupam Dhasmana et al, 2023, Computational and Structural Biotechnology Journal CrossRef
10. A case of ductal carcinoma in situ (DCIS) with markedly elevated CA15-3 levels requiring 2 years of diagnosis
    Mutsumi Fujimoto et al, 2023, Surgical Case Reports CrossRef
11. Upregulation of ABLIM1 Differentiates Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma and Both Colorectal and Pancreatic Adenocarcinoma Liver Metastases
    Tina Draškovič et al, 2024, Genes CrossRef
12. Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer
    Kenji Nakahama et al, 2023, Cancer Chemotherapy and Pharmacology CrossRef
13. Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials
    Muhammet Ozer et al, 2023, Cancers CrossRef
14. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer
    Aying Wang et al, 2023, Cellular Immunology CrossRef
15. The Role of MUC1 in Renal Cell Carcinoma
    Martina Milella et al, 2024, Biomolecules CrossRef
16. Dual Approaches in Oncology: The Promise of siRNA and Chemotherapy Combinations in Cancer Therapies
    Carolina Sousa et al, 2025, Onco CrossRef
17. Adoptive cell therapies in thoracic malignancies: a comprehensive review
    Yago Garitaonaindia et al, 2025, Clinical and Translational Oncology CrossRef
18. A Case of Solitary Pancreatic Metastasis from Gallbladder Cancer
    Shinya Kosuge et al, 2023, The Japanese Journal of Gastroenterological Surgery CrossRef
19. Immunoengineering can overcome the glycocalyx armour of cancer cells
    Sangwoo Park et al, 2024, Nature Materials CrossRef
20. MUC1 expression is associated with ST3GAL2 and negatively correlated with the androgen receptor in castration-resistant prostate cancer
    Shotaro Nakanishi et al, 2024, Glycoconjugate Journal CrossRef
21. Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges
    Wojciech Szymanowski et al, 2023, Cancers CrossRef
22. Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments
    Maurizio Capuozzo et al, 2024, Molecular and Cellular Probes CrossRef
23. Tn antigen interactions of macrophage galactose-type lectin (MGL) in immune function and disease
    Berna Tumoglu et al, 2023, Glycobiology CrossRef
24. Unveiling 8,12‐Dimethoxysanguinarine: A Potent Inhibitor of Breast Cancer Metastasis via Fibronectin 1 Downregulation
    Xiuli Xi et al, 2025, Chemistry & Biodiversity CrossRef
25. EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer
    Huilin Cui et al, 2024, Frontiers in Oncology CrossRef
26. An oncolytic adenovirus co-expressing a bi-specific T cell engager and IL-2 for the treatment of ovarian cancer
    Kalkidan Ayele et al, 2024, Molecular Therapy CrossRef